PIK3CG is altered in 3.0% of malignant solid tumor patients [3].

PIK3CG is an inclusion criterion in 14 clinical trials for malignant solid tumor, of which 11 are open and 3 are closed. Of the trials that contain PIK3CG status and malignant solid tumor as inclusion criteria, 6 are phase 1 (4 open), 3 are phase 1/phase 2 (3 open), and 5 are phase 2 (4 open) [4].

PIK3CG is altered in 1.72% of breast carcinoma patients [3].

PIK3CG is an inclusion criterion in 7 clinical trials for breast carcinoma, of which 7 are open and 0 are closed. Of the trials that contain PIK3CG status and breast carcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [4].

PIK3CG is altered in 4.36% of non-small cell lung carcinoma patients [3].

PIK3CG is an inclusion criterion in 3 clinical trials for non-small cell lung carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PIK3CG status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (0 open) [4].

PIK3CG is altered in 4.0% of colorectal carcinoma patients [3].

PIK3CG is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PIK3CG status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [4].

PIK3CG is altered in 0.88% of non-hodgkin lymphoma patients [3].

PIK3CG is an inclusion criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain PIK3CG status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

PIK3CG is altered in 9.31% of melanoma patients [3].

PIK3CG is an inclusion criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3CG status and melanoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].

PIK3CG is altered in 4.91% of squamous cell lung carcinoma patients [3].

PIK3CG is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3CG status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

PIK3CG is altered in 2.43% of head and neck squamous cell carcinoma patients [3].

PIK3CG is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PIK3CG status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].

PIK3CG is altered in 2.01% of renal cell carcinoma patients [3].

PIK3CG is an inclusion criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3CG status and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].

PIK3CG is altered in 1.69% of hepatocellular carcinoma patients [3].

PIK3CG is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3CG status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

PIK3CG is altered in 7.12% of small cell lung carcinoma patients [3].

PIK3CG is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PIK3CG is altered in 5.64% of endometrial carcinoma patients [3].

PIK3CG is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PIK3CG is altered in 3.5% of gastric adenocarcinoma patients [3].

PIK3CG is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3CG status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

PIK3CG is altered in 2.8% of cancer patients [3].

PIK3CG is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and cancer as inclusion criteria, 1 is phase 1 (1 open) [4].

PIK3CG is altered in 2.57% of urothelial carcinoma patients [3].

PIK3CG is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PIK3CG is altered in 1.5% of prostate carcinoma patients [3].

PIK3CG is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [4].

PIK3CG is altered in 1.18% of liposarcoma patients [3].

PIK3CG is an inclusion criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PIK3CG is altered in 1.72% of undifferentiated pleomorphic sarcoma patients [3].

PIK3CG is an inclusion criterion in 1 clinical trial for undifferentiated pleomorphic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and undifferentiated pleomorphic sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PIK3CG is altered in 1.06% of chondrosarcoma patients [3].

PIK3CG is an inclusion criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PIK3CG is altered in 1.01% of ovarian carcinoma patients [3].

PIK3CG is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PIK3CG is altered in 1.4% of osteosarcoma patients [3].

PIK3CG is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PIK3CG is altered in 0.97% of pancreatic carcinoma patients [3].

PIK3CG is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PIK3CG is altered in 0.62% of thyroid gland carcinoma patients [3].

PIK3CG is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PIK3CG is altered in 0.69% of hematologic and lymphocytic disorder patients [3].

PIK3CG is an inclusion criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [4].

PIK3CG is altered in 0.42% of hematopoietic and lymphoid malignancy patients [3].

PIK3CG is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [4].

PIK3CG is altered in 0.38% of hematopoietic and lymphoid system neoplasm patients [3].

PIK3CG is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

PIK3CG is altered in 0.09% of myeloid neoplasm patients [3].

PIK3CG is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

PIK3CG is an inclusion criterion in 1 clinical trial for aggressive systemic mastocytosis, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and aggressive systemic mastocytosis as inclusion criteria, 1 is phase 1 (1 open) [4].

PIK3CG is an inclusion criterion in 1 clinical trial for classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PIK3CG is an inclusion criterion in 1 clinical trial for desmoid-type fibromatosis, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and desmoid-type fibromatosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PIK3CG is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PIK3CG is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

PIK3CG is an inclusion criterion in 1 clinical trial for mast cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and mast cell leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

PIK3CG is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [4].

PIK3CG is an inclusion criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PIK3CG is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].

PIK3CG is an inclusion criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [4].